Journal Title
NEUROMUSCULAR DISORDERS

NEUROMUSCULAR DISORD

ISSN / eISSN
0960-8966 / 1873-2364
Aims and Scope
This international, multidisciplinary journal covers all aspects of neuromuscular disorders in childhood and adult life (including the muscular dystrophies, spinal muscular atrophies, hereditary neuropathies, congenital myopathies, myasthenias, myotonic syndromes, metabolic myopathies and inflammatory myopathies).

The Editors welcome original articles from all areas of the field:
• Clinical aspects, such as new clinical entities, case studies of interest, treatment, management and rehabilitation (including biomechanics, orthotic design and surgery).
• Basic scientific studies of relevance to the clinical syndromes, including advances in the fields of molecular biology and genetics.
• Studies of animal models relevant to the human diseases.

The journal is aimed at a wide range of clinicians, pathologists, associated paramedical professionals and clinical and basic scientists with an interest in the study of neuromuscular disorders.
Subject Area

CLINICAL NEUROLOGY

NEUROSCIENCES

CiteScore
4.60 View Trend
CiteScore Ranking
Category Quartile Rank
Medicine - Pediatrics, Perinatology and Child Health Q1 #71/330
Medicine - Neurology (clinical) Q2 #167/400
Medicine - Neurology Q2 #85/192
Medicine - Genetics (clinical) Q3 #51/99
Web of Science Core Collection
Science Citation Index Expanded (SCIE) Social Sciences Citation Index (SSCI)
Indexed -
Category (Journal Citation Reports 2024) Quartile
CLINICAL NEUROLOGY Q2
NEUROSCIENCES Q3
H-index
89
Country/Area of Publication
UNITED STATES
Publisher
Elsevier Ltd
Publication Frequency
Monthly
Year Publication Started
1991
Annual Article Volume
132
Open Access
NO
Contact
PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OX5 1GB

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation